Acadia Pharmaceuticals Announces Label Update for NUPLAZID; U.S. FDA Revises Boxed Warning To Clarify That Nuplazid Can Be Used To Treat Patients With Parkinson's Disease-Related Hallucinations And Delusions Who Also Have Dementia
Portfolio Pulse from Benzinga Newsdesk
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) announced that the U.S. Food and Drug Administration (FDA) has revised the Boxed Warning for its drug NUPLAZID, clarifying that it can be used to treat patients with Parkinson's disease-related hallucinations and delusions who also have dementia. The update is consistent with the current indication and includes no other changes.
September 18, 2023 | 3:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA's clarification of NUPLAZID's use could potentially increase the drug's market, benefiting Acadia Pharmaceuticals.
The FDA's clarification on the use of NUPLAZID for patients with Parkinson's disease-related hallucinations and delusions who also have dementia could potentially expand the drug's market. This could lead to increased sales and revenues for Acadia Pharmaceuticals, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100